AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
Advanced manufacturing technologies are transforming biopharma production lines, driving efficiency, quality, and scalability to meet growing global demand.
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
Manufacturing breakthroughs are set to transform cell therapy production, paving the way for faster trials and wider patient …
Despite economic caution, pharma and biotech leaders invest boldly to reshape pipelines and accelerate innovation.
Already a subscriber? Log in